323 related articles for article (PubMed ID: 32052681)
21. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.
Mirone G; Perna S; Shukla A; Marfe G
J Cell Physiol; 2016 May; 231(5):1097-105. PubMed ID: 26419617
[TBL] [Abstract][Full Text] [Related]
22. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.
Zhou ZR; Yang ZZ; Wang SJ; Zhang L; Luo JR; Feng Y; Yu XL; Chen XX; Guo XM
Acta Pharmacol Sin; 2017 Apr; 38(4):513-523. PubMed ID: 28042876
[TBL] [Abstract][Full Text] [Related]
23. Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor.
Tomida C; Nagano H; Yamagishi N; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
J Med Invest; 2017; 64(3.4):262-265. PubMed ID: 28954993
[TBL] [Abstract][Full Text] [Related]
24. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C
Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204
[TBL] [Abstract][Full Text] [Related]
25. BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer.
Sriramulu S; Thoidingjam S; Chen WM; Hassan O; Siddiqui F; Brown SL; Movsas B; Green MD; Davis AJ; Speers C; Walker E; Nyati S
J Exp Clin Cancer Res; 2024 Jun; 43(1):163. PubMed ID: 38863037
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
[TBL] [Abstract][Full Text] [Related]
27. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.
Mehta M; Basalingappa K; Griffith JN; Andrade D; Babu A; Amreddy N; Muralidharan R; Gorospe M; Herman T; Ding WQ; Ramesh R; Munshi A
Oncotarget; 2016 Oct; 7(40):64820-64835. PubMed ID: 27588488
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
Huynh H; Ong R; Zopf D
J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK
Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482
[TBL] [Abstract][Full Text] [Related]
30. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
[TBL] [Abstract][Full Text] [Related]
32. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
[TBL] [Abstract][Full Text] [Related]
33. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
34. The ATR inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro.
Guney Eskiler G; Halis H; Hamarat KF; Derlioglu RR; Ugurlu BT; Haciefendi A
Int J Radiat Biol; 2024; 100(5):715-723. PubMed ID: 38421209
[TBL] [Abstract][Full Text] [Related]
35. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of TMPRSS4 Enhances Triple-Negative Breast Cancer Cell Radiosensitivity Through Cell Cycle and Cell Apoptosis Process Impairment.
Assani G; Segbo J; Yu X; Yessoufou A; Xiong Y; Zhou F; Zhou Y
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3679-3687. PubMed ID: 31870109
[TBL] [Abstract][Full Text] [Related]
37. 2-Methoxyestradiol, an endogenous estrogen metabolite, sensitizes radioresistant MCF-7/FIR breast cancer cells through multiple mechanisms.
Salama S; Diaz-Arrastia C; Patel D; Botting S; Hatch S
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):231-9. PubMed ID: 21392897
[TBL] [Abstract][Full Text] [Related]
38. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
Aprile G; Macerelli M; Giuliani F
BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
[TBL] [Abstract][Full Text] [Related]
39. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
[TBL] [Abstract][Full Text] [Related]
40. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
